Amylx Pharmaceuticals Inc vs Omnicom Group Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Omnicom Group Inc. trades at $85.74 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 8.9× Amylx Pharmaceuticals Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OMC | |
|---|---|---|
Market Cap | $2.64B | $23.58B |
Sector | Health | Media |
52-Week High | $24.19 | $86.22 |
52-Week Low | $7.82 | $67.27 |
Enterprise Value | $2.39B | $31.66B |
Dividend Yield | — | 3.72% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →